Pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, was recently approved for the treatment of microsatellite instability–high, or MMR-deficient solid cancers in adults and children, for all tumor locations and histological types [167]. The gene discussed is PDCD1; the disease is neoplasm.